Since the generation of induced pluripotent stem cells in 2006, cellular reprogramming has attracted increasing attention as a revolutionary strategy for cell replacement therapy. Recent advances have revealed that somatic cells can be directly converted into other mature cell types, which eliminates the risk of neoplasia and the generation of undesired cell types. Astrocytes become reactive and undergo proliferation, which hampers axon regeneration following injury, stroke, and neurodegenerative diseases. An emerging technique to directly reprogram astrocytes into induced neural stem cells (iNSCs) and induced neurons (iNs) by neural fate determinants brings potential hope to cell replacement therapy for the above neurological problems. Here, we discuss the development of direct reprogramming of various cell types into iNs and iNSCs, then detail astrocyte-derived iNSCs and iNs in vivo and in vitro. Finally, we highlight the unsolved challenges and opportunities for improvement.
Introduction
reaching and repopulating target sites [1] .
In 2006, Takahashi and Yamanaka reported the production of induced pluripotent stem cells (iPSCs) from mouse embryonic and adult fi broblasts by introducing four transcription factors, and further demonstrated that iPSCs exhibit the morphology and growth properties of embryonic stem cells (ESCs) as well as expressing marker genes of ESCs [2] ; this has opened up a new era of regenerative medicine. This cellular reprogramming of fibroblasts, one type of terminally differentiated cells, into iPSCs is a novel technique to produce patient-specific cells for autologous transplantation, establish human disease models, and assist drug screening. Thus since then, research teams worldwide have been enthusiastic about iPSC research.
However, Ben-David and Benvenisty reported that the capabilities of self-renewal and multilineage differentiation, two properties of iPSCs, make them tumorigenic [3] . Also, the transcription factors commonly used for reprogramming are highly expressed in various types of cancers and integrating vectors increase the risk of genetic alterations [3] .
So overcoming these limitations is paramount before the widespread therapeutic use of iPSCs. Taking into account these limitations, research workers are now striving to investigate the possibility of direct reprogramming of a committed differentiated cell into targeted cell lines. This emerging technology seems promising for stem cell-based approaches. It has already been reported that human and mouse fibroblasts can be converted into cardiocytes [4] , hepatocytes [5] and neurons [6] by transduction with defined factors. Other cell types, such as astrocytes, can be directly reprogrammed into neuronal lineage cells. Astrocytes are the most plentiful cells in the human brain and play a vital role in glial scar formation following neurological insults. Glial scarring, known as reactive astrogliosis, on one hand protects neuronal networks from further damage [7] and on the other hand acts as a primary barrier to functional regeneration [8] . In addition, properties such as cell proliferation and proximity in lineage distance make astrocytes the ideal candidate cell-type to transdifferentiate into neurons [9] . by the ectopic expression of three transcription factors, Ascl1, Brn2, and Myt1l [10] . The conversion rate was up to 19.5%. However, further exploration is needed, for only a few induced neurons have been identified as GABAergic neurons, without other types of iNs. Recent progress has generated mouse ESC-derived GABAergic neurons [11] , glutamatergic neurons [12] , motor neurons [13] , layer V/ VI corticofugal projection neurons derived from layer II/ III callosal projection neurons [14] , and fibroblast-derived induced dopaminergic (iDA) cells [15] [16] [17] . Not only mouse but also human fibroblasts have changed their cell types toward dopaminergic neurons [17] . [16] .
The functional neurons present a dopaminergic phenotype [17] . In addition, Liu et al.
not only have described the characteristics of iDA cells in vitro but also provided evidence of symptomatic relief like stabilization of rotational behavior in a rat model of
Parkinson disease after iDA cell transplantation [15] . [18] . However, the trouble is that the reprogrammed cells undergo incomplete reprogramming, in that they do not possess all the properties of NSCs. For instance, one of the important properties of NSCs is the capacity to expand, whereas neural precursor cells (NPCs) show poor self-renewal, with no more than three passages. Another defect of NPCs is that they cannot differentiate into oligodendrocytes.
To overcome these limitations, Lujan et al. successfully generated self-renewing tripotent NPCs, which produced neurons, astrocytes, and oligodendrocytes [19] . [20] ; the differentiation rates are 100%, 30%, and 3% when iNSCs are cultured in different media. iNSCs can also self-renew and expand for >50 passages. Similarly, although the iNSCs generated by Han et al. can differentiate into all neural cell lineages, they also have low effi ciency in oligodendrocytes differentiation [21] . one transcription factor, Sox2 [22] , reducing the number of activated oncogenes in the reprogramming process.
Many studies have focused on direct neural reprogramming in vitro. Later, it was reported that beta cell and cardiomyocyte conversion can occur in vivo [23, 24] . neurons from embryonic or early postnatal neurons using the transcription factor Fezf2 in vivo [14, 25] . The fact that neurological disorders are more prevalent in the aging population raises a problem of whether the adult brain must overcome more obstacles when switching cell identity. It has been reported that astrocytes from adult brain can undergo fate changes in vivo [26] [27] [28] . Neuron-to-neuron and astrocyte-to-neuron are two major foci in the fi eld of in vivo reprogramming. Actually, the literature has reported direct reprogramming of astrocytes into neurons in situ.
Directing Reprogramming of Astrocytes in vitro
As astrocytes are terminally differentiated, why have they been selected as a starting cell? The reasons are manifold [29] . First, they are spatially ubiquitous throughout the nervous system. Compared with the NSCs in the subventricular zone (SVZ) of lateral ventricles and the dentate gyrus of the hippocampus, the conscription of astrocytes is not confined by limited resources and sophisticated migration. Second, astrocytes share many characteristics with radial glia, the NSCs [30] capable of generating neurons, astrocytes, and oligodendrocytes.
Third, injury and a favorable environment induce astrocytes into tripotent differentiating and self-renewing cells [31] . Accordingly, astrocytes are likely to be ideal starting cells for neuronal conversion in neuronal injury or neurodegenerative diseases.
There are two states of astroglia: quiescent and reactive. The difference between them is that quiescent astrocytes cannot divide, but resume proliferation and differentiation after being activated by injury [31] or other pathological conditions like stroke [32] and neurodegenerative disease [33] . The astrocytes activated under pathological conditions are reactive. The postnatal stage astrocyte, which can retain potential for neurogenesis, is intermediate between radial glia and quiescent astroglia [29] . Indeed, an earlier study revealed that early postnatal astrocytes give rise to multilineage precursors and NSCs [34] . Several reports [35] [36] [37] [38] have shown that reactive astroglia in the injured brain have increased plasticity and acquire the potential of NSCs. Activated astrocytes can self-renew and are able to differentiate into neurons, astrocytes, and oligodendrocytes in vitro [35, 37, 38] . However, Buffo et al. and Shimada et al. failed to verify that reactive astrocytes can generate neurons in vivo [31, 37] . Nevertheless, reactive astrocytes still seem to be a promising cell type for further exploration of regenerative medicine.
Astrocytes are able to give rise to neurons or NSCs when provided with proper transcription cues in vitro [39] [40] [41] [42] .
Astrocytes from early postnatal cerebral cortex infected by Pax6-encoding virus transform into neurons [39] .
However, there is no evidence of whether these neurons are functional and which types they belong to. Therefore, to further answer these questions, Berninger et al.
started to study the physiological properties of astrogliaderived neurons [40] . They used the other proneural genes neurogenin-2 and Mash1 which are also able to induce 
Directing Reprogramming of Astrocytes in vivo
In addition to studies demonstrating that reactive After facilitation, the differentiated neurons have electrophysiological functionality, so that they integrate into local neuronal circuitry. It is worth mentioning that the differentiation effi ciency of iANBs is no more than 0.3%, so they are less valuable for clinical application compared to iNs. In another study, SOX2 was also capable of inducing resident astrocytes in the injured adult spinal cord into neuroblasts. The histone deacetylase inhibitor likewise promoted neuronal maturation, leading neuroblasts to form synapse-forming neurons in vivo [26] .
Direct neuronal conversion has also been performed in vivo [28, 43] . Torper et al. provided the first evidence of conversion of endogenous astrocytes to iNs following infection with Ascl1, Brn2a, and Myt11 Cre-inducible lentiviral vectors [43] . The reprogrammed cells fi nally showed neuronal morphology and expressed NeuN. The restriction of this study is that the phenotypes and functions of the iNs were not explored. Recently, Guo et al. have made great strides in direct neuronal cell fate conversion [28] . Most issues that remain to be solved [45] . Besides the known 
iNSCs or iNs, Which Will Be a Therapeutic Option in Future?
We rate the current achievements in direct reprogramming [49, 50] . Third, NSC treatment enhances dendritic plasticity, increases axonal rewiring, and facilitates axonal transport, all of which are critical for axonal function and may improve functional recovery [51] . Fourth, anti-apoptosis is also involved. Xia et al. found that NSCs down-regulate the expression of apoptosis genes, coinciding with a decrease of apoptotic cells in lesions [52] . Finally, iNSC therapy protects the injured brain in mice with stroke partly through enhanced neurogenesis and angiogenesis [53] . In conclusion, the profiles of NSCs, such as anti-inflammatory function, modulation of the immune response, trophic effects, enhanced structural plasticity, anti-apoptosis potential, neurogenesis, and angiogenesis as well as self-renewal and differentiation, have attracted attention. However, the major challenge of directing the fate of iNSCs to specific neuronal subtypes to replace neurons lost to disease remains unsolved. Besides, the low differentiation rate [27] and tumorigenicity are stumbling blocks. [22, 27, 42] , iNSCs can lead to tumor formation if their growth is unlimited or growth control is impaired. Consequently, further studies are warranted to fully evaluate the tumorigenic potential of such therapy.
iNs are terminally-differentiated mature cells, thus circumventing the pluripotent stage, shortening the experimental procedures and avoiding re-differentiation processes [54] . So far, astrocyte-derived neurons include iDA, GABAergic, motor, and glutamatergic neurons. Parkinson disease, characterized by the loss of iDA neurons in the substantia nigra of the midbrain, shows symptomatic relief after treatment with DA neurons [15] . In a sense, iNs might hold promise as a replacement for iNSCs in certain how does that infl uence their functionality [9] ? In conclusion, it is difficult to reach agreement as to which is better, since iNSCs and iNs each have their advantages and disadvantages.
Challenges for Direct Conversion of Astrocytes in the Central Nervous System
Although both iNSCs and iNs can be generated from 
Vectors
Given that viral vectors are comparatively efficient, researchers have principally used lentiviral or retroviral vectors for gene delivery in pre-clinical studies.
Notwithstanding their efficiency, viral vectors also pose a series of risks including insertional mutagenesis, transgene integration, cell senescence, strong immunogenicity [55] and viral infection. Now investigators are seeking an ideal vector for gene delivery to alleviate these potential risks.
Most importantly, an ideal vector [56] would avoid vectorrelated side-effects and efficiently transduce the starting cells, tissues, or organs while minimally transducing unrelated targets. Then the ideal vector would express the transcription factors at appropriate levels and for a sufficient length of time without multiple transfections.
Although the ideal vector has not been developed, these
properties provide hints for currently-available vectors to further facilitate transgene expression and even reprogramming technologies. As the potential risks caused by transgene integration are the major concern, a series of studies have focused on polycistrons [57] , the Cre-LoxP system [58] , plasmids [59] , episomal vectors [60] , RNA, PiggyBac transposition [61] , proteins [62, 63] , and adeno-associated virus (AAV) to eliminate or avoid gene integration and achieve safe delivery. Here, we cite several instances, beginning with more details about RNA. microRNAs not only play a crucial role in the transcription process in regulating gene expression after transcription, but also participate in the progress of reprogramming. For instance, it has been demonstrated that microRNA and neurogenic transcription factors induce the cell-fate change toward functional neurons [64] . In the same year, Ambasudhan et al. acquired human fibroblasts-derived neurons with a combination of miR-124 and two reprogramming factors, MYT1L and BRN2 [65] . This indicates that microRNAs play an essential role in neuron formation, so it is thought that microRNAs can help develop a vector-free strategy. Cotransfection with miR-375 and miR-186 differentiates iPSCs to insulin-like cell clusters [66] . This provides hints for the direct conversion of astrocytes. Besides microRNAs, mRNA encoding reprogramming factors are transfected into human cells to induce pluripotency with high effi ciency, but this needs repetitive transfections [67] . This mRNA-based technology shows no genome integration. The Cre-Loxp system is also under investigation. The transgenes are first integrated, then are excised from the reprogrammed genome by the Cre-Loxp system, reducing the potential for transcription factor integration [58] . Finally, we should mention that AAV is a promising vector for gene delivery. It exhibits no pathogenicity and high effi ciency, so it has been widely used in animal experiments [68] and clinical trials [69] . However, AAV also faces challenges, such as controlling transgene expression and increasing cellular targeting specificity [70] .
In hypoxia without introducing exogenous factors [71] .
Transcription Factors
As for transcription factor screening, optimized factors should be safe and have high efficiency. Reprogramming factors can result in uncontrolled reactivation and residual expression, which may fi nally lead to tumor formation and gene mutation. In terms of safety, most transcription factors, known as oncogenes, are associated with cancer. The stem-cell marker genes Sox2, Oct4, and Nanog have been detected in samples of bladder carcinomas, colon cancer, and prostate cancer, as well as other cancers [72] . Taking Sox2 as an example, it is overexpressed in squamous cell carcinomas in several tissues such as the lung [73] , hypopharynx, larynx, and sinonasal area [74] . Besides safety, the combination of transgenes is also related to effi ciency.
In a study by Vierbuchen et al., the conversion rate in the Ascl1, Brn2, and Myt1l pool was 2-3-fold higher than that in the Ascl1, Brn2, Myt1l, Zic1, and Olig2 pool [10] . Taken together, transgene-free reprogrammed cells need further investigation, and may become an emerging strategy in regenerative medicine.
Mechanisms
In the years to come, other than developing ideal vectors and vector-free or transgene-free strategies, better understanding of the exact underlying mechanisms is needed. If all the mechanisms of the reprogramming process are clearly elucidated, the currently perplexing technological hurdles can be overcome and probably only simple signaling molecules can be used to regulate genetic manipulation.
Conclusion
The generation of iNs and iNSCs by direct reprogramming and even organs [75] . Therefore, direct reprogramming from astrocytes into iNSCs or iNs may be advantageous for injection. Even more, cells can be targeted by chemical stimuli [71] . Notwithstanding the many unsolved problems, direct reprogramming of astrocytes has profound implications in the fi eld of neurological disorders.
